Comparative Pharmacokinetics of Tixagevimab/Cilgavimab (AZD7442) Administered Intravenously Versus Intramuscularly in Symptomatic SARS‐CoV‐2 Infection

AZD7442 (Evusheld) is a combination of two human anti‐severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2) monoclonal antibodies (mAbs), tixagevimab (AZD8895) and cilgavimab (AZD1061). Route of administration is an important consideration to improve treatment access. We assessed pharmacokine...

Descripción completa

Detalles Bibliográficos
Autores principales: Bender Ignacio, Rachel A., Wohl, David A., Arends, Rosalin, Pilla Reddy, Venkatesh, Mu, Ying, Javan, Arzhang Cyrus, Hughes, Michael D., Eron, Joseph J., Currier, Judith S., Smith, Davey, Chew, Kara W., Gibbs, Michael, Fletcher, Courtney V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9349574/
https://www.ncbi.nlm.nih.gov/pubmed/35797235
http://dx.doi.org/10.1002/cpt.2706

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9349574/
https://www.ncbi.nlm.nih.gov/pubmed/35797235
http://dx.doi.org/10.1002/cpt.2706

Ejemplares similares